Universität zu Köln

Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140. S. 19 - 24. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Brown, Jennifer. R. R., Eichhorst, Barbara, Hillmen, Peter, Jurczak, Wojciech, Kazmierczak, Maciej, Lamanna, Nicole, O'Brien, Susan. M. M., Tam, Constantine. S. S., Qiu, Lugui, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter. S. S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte. A. A., Salmi, Tommi, Wang, Megan-Der-Yu, Fu, Lina., Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar . Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med.. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Hallek, Michael, Kay, Neil E., Osterborg, Anders, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Wan, Ying, Sun, Steven, Zhuang, Sen Hong and Howes, Angela (2015). The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol., 11 (1). S. 51 - 60. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Fardis, Maria, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan (2014). Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE (TM)-17 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven E., Mato, Anthony R., Hillmen, Peter, Tam, Constantine ORCID: 0000-0002-9759-5017, Osterborg, Anders, Siddiqi, Tanya ORCID: 0000-0001-5292-8298, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael J., Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan (2016). Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol., 17 (10). S. 1409 - 1419. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Stilgenbauer, Stephan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Li, Yunfeng, Eckert, Karl, Chang, Betty Y., James, Danelle F., Chu, Alvina D., Hallek, Michael and O'Brien, Susan (2015). Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020